Page 23 - Lupin

Lupin, Boehringer to co-market two oral anti-diabetic drugs in India

The two drugs, Gibtulio Met and Ajaduo, will be co-marketed simultaneously by Boehringer Ingelheim and Lupin across India under different brand names

Lupin hits over four month high; stock rises 5% in two days

In past one month, Lupin has outperformed the market by surging 23% as compared to 1.4% rise in the S&P BSE Sensex.

Lupin Pharmaceuticals' smooth-run in Japan; all eyes on biosimilars growth

Lupin's Japan story assumes significance as it held on to the highly regulated market, when most of its Indian peers quit

Lupin rises 2% on partnership with Mylan for Enbrel Biosimilar

Under the terms of the agreement, Lupin will receive an up-front payment of $15 million and potential commercial milestones together with an equal share in net profits of the product.

Lupin, Nichi-Iko to commercialise arthritis biosimilar in Japan

Etanercept is used in treatment of auto immune diseases such as rheumatoid arthritis, plaque psoriasis, psoriatic arthritis and ankylosing spondylitis

Lupin launches drug to control postpartum hemorrhage after USFDA nod

Lupin's product is the generic equivalent of Novartis Pharmaceuticals Corp's Methergine

Lupin showing signs of revival under its second-generation leadership team

But the going is still tricky

Lupin gains on EIR from USFDA for Pithampur Unit 1

At 10:41 am; the stock was trading 3% higher at Rs 808 after rallied 7% to Rs 843 on the NSE in intra-day trade

Lupin extends gain as UK MHRA completes inspection at Goa unit

The stock was up 3% to Rs 798, extending its Monday's 5% surge on the BSE

Lupin stock in 2017 global worst-performer list, says Evaluate report

US Food and Drug Administration's warning letters to two Lupin plants in Goa and Indore in November was the main reason for the decline in the stock price

Lupin hits 52-week low on weak Q3 results

The stock hit 52-week low of Rs 782, down 2.5% in intra-day trade, extending its previous day's 6% decline on BSE

Lupin: Q3 shows further rise in US pricing pressure as net profit falls 65%

Gross profit margins fell to a 16-quarter low, pulling down earnings by 65% y-o-y

Lupin extends gain; up 5% in four trading sessions

The stock moved higher by nearly 2% to Rs 852, extending its past three days 3.5% gain on the BSE

Lupin gets USFDA warning for Goa & Pithampur plants, stock tanks 15%

While the company can continue to supply existing products to the US market, fresh approvals will be delayed.

Lupin tanks 17%, hits over 3-year low as USFDA issues warning letter

The stock tanked 15% to Rs 880 on the BSE, trading at its lowest level since January 1, 2014.

US sales pressure hurts Lupin again

Growth in other geographies points to a better second half

Lupin Q2 profit down 31% at Rs 455 cr, but slightly above consensus

The drugmaker profit came in at Rs 455 cr for the quarter ended Sept 30, compared with Rs 662 cr a year earlier

Lupin surges 7% post September quarter earnings

The stock has moved higher by 7% to Rs 1,074 after the company reported a consolidated net profit of Rs 455 crore in Q2FY18

Lupin gets US FDA nod for carbidopa tablets to treat Parkinson's disease

Carbidopa tablets, 25 mg had annual sales of approximately $21.9 million in the US

Lupin: Price erosion still a key concern

Recent acquisition & large product pipeline long-term growth drivers; price erosion in US to weigh on earnings